Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B

Wiens, Astrid; Venson, Rafael; Januário Correr, Cassyano; Pontarolo, Roberto

doi:10.1016/S1413-8670(11)70180-5

Article information

Abstract

Bibliography

Download PDF

Statistics

Abstract

Background and aim

Chronic hepatitis B is a highly prevalent disease worldwide, leading to serious consequences if not properly treated. Six treatment options for chronic hepatitis B are currently provided by the Brazilian public health system. Telbivudine is a nucleoside analogue that is neither included in the Brazilian clinical protocol nor in the therapeutic guidelines for chronic hepatitis B.

Objective

The aim of this study was to evaluate the cost-effectiveness of telbivudine for the viewpoint of the Brazilian public system, comparing it to lamivudine.

Methods

A Markov model was used to project lifetime complications and costs of treatment with lamivudine or telbivudine for chronic hepatitis B in both HBeAg-positive and HBeAg-negative patients. To evaluate disease progression, probabilities and utilities of virologic response, virologic resistance, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, treatment, interruption of treatment, death and seroconversion were collected in systematic reviews. Costs were collected in DATASUS, ABC da Saúde and scientific literature.

Results

Higher rate of virologic response and seroconversion was obtained with telbivudine, and also higher values of quality adjusted life years. However lamivudine is associated with lower costs and also lower cost-effectiveness values. The incremental cost-effectiveness ratios for telbivudine, when compared with lamivudine, were US$ 30,575 and US$ 40,457, respectively for HBeAg-positive and HBeAg-negative patients.

Conclusions

In chronic hepatitis B lamivudine is a more cost-effective or even cost-saving strategy when compared with telbivudine

Keywords:

lamivudine

cost-effectiveness evaluation

hepatitis B

chronic

Full text is only aviable in PDF

References

[1.]

H.M. Elgouhari, T.I. Abu-Rajab Tamimi, W.D. Carey.

Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis.

Cleve Clin J Med., 75 (2008), pp. 881-889

http://dx.doi.org/10.3949/ccjm.75a.07019 | Medline

[2.]

E. Palumbo.

Lamivudine for chronic hepatitis B: a brief review.

Braz J Infect Dis., 12 (2008), pp. 355-357

Medline

[3.]

R. Barcena Marugan, S. Garcia Garzon.

DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

World J Gastroenterol., 15 (2009), pp. 423-430

Medline

[4.]

F.J. Souto, A.C. Piraja, G.S. da Silva, M. Bottecchia, S.A. Gomes.

Long-term use of lamivudine for treating chronic hepatitis B in the State of Mato Grosso.

Rev Soc Bras Med Trop., 40 (2007), pp. 18-24

Medline

[5.]

E.B. Keeffe, D.T. Dieterich, S.H. Han, et al.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.

Clin Gastroenterol Hepatol., 6 (2008), pp. 1315-1341

http://dx.doi.org/10.1016/j.cgh.2008.08.021 | Medline

[6.]

A.S. Lok, B.J. McMahon.

Chronic hepatitis B.

Hepatology, 45 (2007), pp. 507-539

http://dx.doi.org/10.1002/hep.21513 | Medline

[7.]

M.H. Nguyen, E.B. Keeffe.

Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.

J Viral Hepat., 16 (2009), pp. 149-155

http://dx.doi.org/10.1111/j.1365-2893.2009.01078.x | Medline

[8.]

Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas para o Tratamento da Hepatite Viral Crônica B e Coinfecções. In: Secretaria de Vigilância em Saúde - Departamento de DST AeHV, editor.: Programa Nacional para a Prevenção e o Controle das Hepatites Virais; 2009. p. 128.

[9.]

M.S. Ferreira, A.S. Borges.

Advances in the treatment of hepatitis B.

Rev Soc Bras Med Trop., 40 (2007), pp. 451-462

Medline

[10.]

N. Kurashige, K. Ohkawa, N. Hiramatsu, et al.

Lamivudine-toentecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.

J Gastroenterol, 44 (2009), pp. 864-870

http://dx.doi.org/10.1007/s00535-009-0076-0 | Medline

[11.]

M.S. Ferreira.

Diagnosis and treatment of hepatitis B.

Rev Soc Bras Med Trop., 33 (2000), pp. 389-400

Medline

[12.]

C.L. Lai, E. Gane, Y.F. Liaw, et al.

Telbivudine versus lamivudine in patients with chronic hepatitis B.

N Engl J Med., 357 (2007), pp. 2576-2588

http://dx.doi.org/10.1056/NEJMoa066422 | Medline

[13.]

Y.F. Liaw, E. Gane, N. Leung, et al.

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

Gastroenterology, 136 (2009), pp. 486-495

http://dx.doi.org/10.1053/j.gastro.2008.10.026 | Medline

[14.]

D.M. Mota.

Avaliação Farmacoeconômica instrumento de medida dos benefícios na atenção farmacêutica.

Acta Farm Bonaerense, 22 (2003), pp. 73-80

[15.]

A. Brennan, N. Bansback, A. Reynolds, P. Conway.

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

Rheumatology (Oxford), 43 (2004), pp. 62-72

[16.]

A. Castelo, M.G. Pessoa, T.C. Barreto, M.R. Alves, D.V. Araujo.

Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005.

Rev Assoc Med Bras., 53 (2007), pp. 486-491

Medline

[17.]

J. Hou, Y.K. Yin, D. Xu, et al.

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

Hepatology, 47 (2008), pp. 447-454

http://dx.doi.org/10.1002/hep.22075 | Medline

[18.]

U.H. Iloeje, H.I. Yang, J. Su, C.L. Jen, S.L. You, C.J. Chen.

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Gastroenterology, 130 (2006), pp. 678-686

http://dx.doi.org/10.1053/j.gastro.2005.11.016 | Medline

[19.]

C.J. Chen, H.I. Yang, U.H. Iloeje.

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.

Hepatology, 49 (2009), pp. S72-S84

http://dx.doi.org/10.1002/hep.22884 | Medline

[20.]

D.L. Veenstra, S.D. Sullivan, M.Y. Lai, C.M. Lee, C.M. Tsai, K.K. Patel.

HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.

Value Health, 11 (2008), pp. 131-138

http://dx.doi.org/10.1111/j.1524-4733.2007.00221.x | Medline

[21.]

E.T. Lam, C.L. Lam, C.L. Lai, M.F. Yuen, D.Y. Fong, T.M. So.

Health-related quality of life of Southern Chinese with chronic hepatitis B infection.

Health Qual Life Outcomes, 7 (2009), pp. 52

http://dx.doi.org/10.1186/1477-7525-7-52 | Medline

[22.]

A.R. Levy, K.V. Kowdley, U. Iloeje, et al.

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

Value Health, 11 (2008), pp. 527-538

http://dx.doi.org/10.1111/j.1524-4733.2007.00297.x | Medline

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter